Thrombosis and Haemostasis · 2012 · 28 citations · 29 references
MedicineHematologyPathologyHematology PhysiologyHematopathologyHemostasisPlatelet FunctionPlatelet PhysiologyThromboembolic DiseaseThrombosisThrombotic DisordersVenous ThromboembolismEndothelial Procoagulant ActivityFactor V Leiden ThrombophiliaHereditary Factor V DeficiencyThrombosis BiomarkersThrombosis MechanismsThrombosis PathophysiologyThrombotic Risk AssessmentThrombotic Risk Stratification
Although factor V Leiden (FVL) is a major determinant of thrombotic risk, the reason why less than 10% of carriers eventually develop venous thromboembolic (VTE) events is unknown. Recent observations suggest that circulating levels of microparticles (MP) may contribute to the thrombogenic profile of FVL carriers. We measured the plasma level of annexin V-MP (AMP) platelet-MP (PMP), endothelial-MP (EMP), leukocyte-MP (LMP) and tissue factor-bearing MP (TF(+)MP), and the MP procoagulant activity (PPL) in 142 carriers of FVL (of these 30 homozygous and 49 with prior VTE), and in 142 age and gender-matched healthy individuals. The mean (± SD) level of AMP was 2,802 ± 853 MP/μl in carriers and 1,682 ± 897 in controls (p<0.0001). A statistically significant difference between homozygous and heterozygous carriers of FVL was seen in the level of PMP, EMP and LMP, but not in that of the remaining parameters. When the analysis was confined to carriers with and without a VTE history, the mean level of AMP was 3,110 ± 791 MP/μl in the former, and 2,615 ± 839 MP/μl in the latter (p<0.005). The mean level of all subtypes of circulating MP showed a similar pattern. The PPL clotting time was 39 ± 9 seconds (sec) in carriers, and 52 ± 15 sec in controls (p=0.003); and was 35 ± 8 sec in carriers with prior thrombosis, and 41 ± 10 sec in thrombosis-free carriers (p<0.005). Our study results suggest that circulating MP may contribute to the development of thrombosis in carriers of FVL mutation.
29
Mutation in blood coagulation factor V associated with resistance to activated protein C
Rogier M. Bertina, Bobby P. C. Koeleman, Ted Koster et al. · Nature · 1994 · 3.8K citations
Medicine, Genetics, Hematology +14
Risk Factors for Venous Thrombotic Disease
Frits R. Rosendaal · Thrombosis and Haemostasis · 1999 · 377 citations
Paolo Simioni, Paolo Prandoni, Anthonie W.A. Lensing et al. · New England Journal of Medicine · 1997 · 373 citations · Full text
Medicine, Genetics, Hematology +17
Romaric Lacroix, Stéphane Robert, Pascal Poncelet et al. · Journal of Thrombosis and Haemostasis · 2010 · 345 citations · Full text
Medicine, Cell Biology, Hematology +12